Effect of Dimenhydrinate on Heart Rate Variability (HRV)

Assessment of Cardiac autonomic system responses to oral administration of Dimenhydrinate in healthy young subjects

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230606058390N1

Enrollment

Registered

2023-07-01

Start date

2023-07-06

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Assessment of Cardiac autonomic system responses to oral administration of Dimenhydrinate in healthy subjects.

Interventions

At the beginning of the intervention, each participant is given a pack with a three-digit code that contains 50 mg Dimenhydrinate tablets or placebo, then every half an hour, ECG is taken using HRV re

Eligibility

Sex/Gender

All

Age

19 Years to 26 Years

Inclusion criteria

Inclusion criteria: Healthy subjects Normal Body Mass Index (BMI) 19 to 26 years olds

Exclusion criteria

Exclusion criteria: Smoking Alcohol consumption Substance abuse Cardiovascular diseases Acute and chronic diseases Prohibition of Dimenhydrinate

Design outcomes

Primary

Measure	Time frame
The effect of Dimenhydrinate 50 mg tablets on HRV. Timepoint: Before starting the intervention and every 30 minutes after the start of taking Dimenhydrinate tablets 50 mg or placebo for 4 hours. Method of measurement: HRV recording device and eprobe software.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Roghayeh Pourkia

Babol University of Medical Sciences

dr.pourkia@yahoo.com+98 11 3219 9592

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026